KR20230156436A - 골드 키위 조성물과 준비 방법 및 그 사용 - Google Patents

골드 키위 조성물과 준비 방법 및 그 사용 Download PDF

Info

Publication number
KR20230156436A
KR20230156436A KR1020237037806A KR20237037806A KR20230156436A KR 20230156436 A KR20230156436 A KR 20230156436A KR 1020237037806 A KR1020237037806 A KR 1020237037806A KR 20237037806 A KR20237037806 A KR 20237037806A KR 20230156436 A KR20230156436 A KR 20230156436A
Authority
KR
South Korea
Prior art keywords
composition
gold
kiwi
powder
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237037806A
Other languages
English (en)
Korean (ko)
Inventor
줄리엣 안셀
폴 블라취포드
Original Assignee
아나제닉스 아이피 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아나제닉스 아이피 리미티드 filed Critical 아나제닉스 아이피 리미티드
Publication of KR20230156436A publication Critical patent/KR20230156436A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A23L19/01—Instant products; Powders; Flakes; Granules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020237037806A 2014-11-28 2015-11-27 골드 키위 조성물과 준비 방법 및 그 사용 Pending KR20230156436A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
NZ70245414 2014-11-28
NZ702454 2014-11-28
NZ706405 2015-03-27
NZ70640515 2015-03-27
PCT/NZ2015/050200 WO2016085356A1 (en) 2014-11-28 2015-11-27 Gold kiwifruit compositions and methods of preparation and use therefor
KR1020177017760A KR102599549B1 (ko) 2014-11-28 2015-11-27 골드 키위 조성물과 준비 방법 및 그 사용

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177017760A Division KR102599549B1 (ko) 2014-11-28 2015-11-27 골드 키위 조성물과 준비 방법 및 그 사용

Publications (1)

Publication Number Publication Date
KR20230156436A true KR20230156436A (ko) 2023-11-14

Family

ID=56074755

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177017760A Active KR102599549B1 (ko) 2014-11-28 2015-11-27 골드 키위 조성물과 준비 방법 및 그 사용
KR1020237037806A Pending KR20230156436A (ko) 2014-11-28 2015-11-27 골드 키위 조성물과 준비 방법 및 그 사용

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020177017760A Active KR102599549B1 (ko) 2014-11-28 2015-11-27 골드 키위 조성물과 준비 방법 및 그 사용

Country Status (16)

Country Link
US (4) US10512663B2 (enExample)
EP (2) EP4548775A3 (enExample)
JP (3) JP7330667B2 (enExample)
KR (2) KR102599549B1 (enExample)
CN (3) CN116763830A (enExample)
BR (1) BR112017011078B1 (enExample)
CA (2) CA3200468A1 (enExample)
DK (1) DK3223838T3 (enExample)
ES (1) ES3023661T3 (enExample)
FI (1) FI3223838T3 (enExample)
MY (1) MY188290A (enExample)
NZ (1) NZ732197A (enExample)
PL (1) PL3223838T3 (enExample)
PT (1) PT3223838T (enExample)
SI (1) SI3223838T1 (enExample)
WO (1) WO2016085356A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3223838T (pt) * 2014-11-28 2025-04-28 Anagenix Ip Ltd Composições de kiwi dourado e métodos de preparação e utilização das mesmas
KR101833504B1 (ko) * 2016-12-26 2018-03-05 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 폐암 진단방법
KR101833348B1 (ko) * 2016-12-26 2018-03-02 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 유방암 진단방법
KR101940426B1 (ko) * 2016-12-28 2019-01-18 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 대장종양 진단 방법
KR101942197B1 (ko) 2016-12-28 2019-01-24 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 전립선질환 진단 방법
US11413318B2 (en) * 2017-06-06 2022-08-16 Sami-Sabinsa Group Limited Compositions and methods for management of atrophic gastritis and colitis
WO2019075273A1 (en) * 2017-10-11 2019-04-18 Gu Jennifer L INTESTINAL HEALTH COMPOSITIONS
KR102130485B1 (ko) * 2017-10-13 2020-07-06 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 알츠하이머치매 진단방법
KR102007786B1 (ko) * 2017-10-18 2019-08-07 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 두경부암 진단방법
WO2019118984A2 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
KR101940950B1 (ko) * 2018-01-23 2019-01-21 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 담관암 진단방법
KR101944662B1 (ko) * 2018-02-14 2019-02-01 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 뇌졸중 진단방법
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
CA3111795A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
CN109288104B (zh) * 2018-11-12 2023-09-01 方家铺子（莆田）绿色食品有限公司 一种桂圆鲜果挂黄处理设备及其处理方法
MX2021008072A (es) 2019-01-18 2021-08-16 Cp Kelco Us Inc Composicion prebiotica y su uso.
CN110279814A (zh) * 2019-06-10 2019-09-27 湖北虹玮农业有限公司 一种用于中老年慢性便秘的功能食品
US11684645B2 (en) * 2019-11-26 2023-06-27 Tci Co., Ltd. Actinidia chinensis Planch ferment and use thereof
WO2022115709A2 (en) * 2020-11-30 2022-06-02 January, Inc. Methods and composition for treating metabolic syndrome
US20220233151A1 (en) * 2021-01-22 2022-07-28 Ethicon Llc Bariatric surgery post-surgical monitoring
KR102543549B1 (ko) * 2021-01-26 2023-06-15 주식회사 다솔마임마케팅사업부 칼라만시 발포정 및 그 제조 방법
CN113521109A (zh) * 2021-06-28 2021-10-22 广州知易生物科技有限公司 解纤维素拟杆菌在预防和/或治疗炎症性肠病中的应用
CN116076711A (zh) * 2021-11-05 2023-05-09 百岳特生物技术（上海）有限公司 益生质组合物及其用途
US12343366B2 (en) * 2021-11-05 2025-07-01 Tci Co., Ltd. Prebiotic composition and method for improving intestinal health using the same
CA3238788A1 (en) 2021-11-22 2023-05-25 Eric Michael Schott Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
JP7701899B2 (ja) * 2022-09-14 2025-07-02 花王株式会社 クロロゲン酸類吸収量の予測方法
KR102536627B1 (ko) * 2022-09-30 2023-05-30 (주)바이텍 키위 발효물을 포함하는 알코올성 간손상 예방 또는 개선용 조성물
US20250195594A1 (en) * 2023-12-18 2025-06-19 First Day Life Inc. Ingestible Nutritive Compositions With Prebiotics, Probiotics, and Postbiotics
US20250195588A1 (en) * 2023-12-18 2025-06-19 First Day Life, Inc. Ingestible Nutritive Compositions With Prebiotics, Probiotics, and Postbiotics
NL2038369B1 (en) * 2024-07-31 2025-03-06 Sunbird Company Ltd A composition of natural kiwifruit powder and postbiotics and its use in constipation improvement

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US22355A (en) 1858-12-21 sherwood
JP2750767B2 (ja) 1990-02-21 1998-05-13 雪印乳業株式会社 新規糖アルコール
NZ235972A (en) 1990-11-06 1995-04-27 Amaranathan Balasingham Fruit product by soft pulping after skin removal
CN1107308A (zh) * 1994-02-25 1995-08-30 中国癌症研究基金会 猕猴桃天然营养口服液
JPH10313822A (ja) 1997-05-20 1998-12-02 Pola Chem Ind Inc 腸内細菌叢改善剤及びそれを含有する組成物
AT503521A1 (de) * 2006-05-05 2007-11-15 Omnica Gmbh Verwendung eines extraktes von kiwi-frucht
NZ554991A (en) * 2007-05-03 2009-11-27 Vital Food Processors Ltd Powdered kiwifruit extract compositions for the treatment of digestive dysfunction and/or gastrointestinal tract disorders
USPP22355P3 (en) * 2009-06-30 2011-12-20 Zespri Group Limited Kiwifruit plant named ‘ZESY002’
AU2011209407B2 (en) * 2010-01-28 2014-02-27 Ab-Biotics S.A. Probiotic composition for use in the treatment of bowel inflammation
PT3223838T (pt) * 2014-11-28 2025-04-28 Anagenix Ip Ltd Composições de kiwi dourado e métodos de preparação e utilização das mesmas

Also Published As

Publication number Publication date
JP2017537156A (ja) 2017-12-14
BR112017011078A2 (pt) 2017-12-26
BR112017011078B1 (pt) 2021-05-11
US20220105145A1 (en) 2022-04-07
CA2967263A1 (en) 2016-06-02
KR102599549B1 (ko) 2023-11-06
NZ769769A (en) 2024-07-26
US20200197460A1 (en) 2020-06-25
CN116270773A (zh) 2023-06-23
ES3023661T3 (en) 2025-06-02
US11642386B2 (en) 2023-05-09
US20170326190A1 (en) 2017-11-16
FI3223838T3 (fi) 2025-05-05
EP3223838A1 (en) 2017-10-04
US11090348B2 (en) 2021-08-17
KR20170088970A (ko) 2017-08-02
EP4548775A2 (en) 2025-05-07
JP2022078050A (ja) 2022-05-24
EP3223838A4 (en) 2018-08-01
FI3223838T8 (fi) 2025-06-16
CN106999523A (zh) 2017-08-01
EP4548775A3 (en) 2025-08-27
PL3223838T3 (pl) 2025-05-26
CN116763830A (zh) 2023-09-19
JP7330667B2 (ja) 2023-08-22
DK3223838T3 (da) 2025-04-28
EP3223838B1 (en) 2025-02-05
SI3223838T1 (sl) 2025-07-31
WO2016085356A1 (en) 2016-06-02
PT3223838T (pt) 2025-04-28
JP2024088715A (ja) 2024-07-02
US20240091291A1 (en) 2024-03-21
JP7471668B2 (ja) 2024-04-22
CA3200468A1 (en) 2016-06-02
NZ732197A (en) 2022-07-01
MY188290A (en) 2021-11-25
US10512663B2 (en) 2019-12-24

Similar Documents

Publication Publication Date Title
US11642386B2 (en) Gold kiwifruit compositions and methods of preparation and use therefor
Del Piano et al. Probiotics: from research to consumer
US20140335066A1 (en) Lactobacillus plantarum inducia dsm 21379 as enhancer of cellular immunity, hypocholesterolemic and anti-oxidative agent and antimicrobial agent against clostridium difficile
CN115804798A (zh) 含微生物的组合物增加丁酸、叶酸或烟酸的肠道生产和/或降低琥珀酸的肠道生产的应用
JP7360420B2 (ja) ディスバイオシスの治療のために用いられるブドウ果皮
KR20210005717A (ko) 프로바이오틱 비피도박테리움 브레베 균주 및 상기 균주를 포함하는 조성물
US20240293483A1 (en) Probiotic composition for the treatment of increased intestinal permeability
US20100143319A1 (en) Kiwifruit compositions
EP2220210B1 (en) Strains of lactobacillus plantarum as probiotics with immunomodulatory specific effect
US12194142B2 (en) Bacillus subtilis containing composition for treatment of gastrointestinal irregularity
US20230310519A1 (en) Use of adlercreutzia bacteria for the treatment of inflammatory diseases
JP7601332B2 (ja) 便秘解消組成物
KR101376629B1 (ko) 신규한 락토바실러스 아리조넨시스 ｂｃｎｕ 9200 균주 및 이를 유효성분으로 포함하는 생균제 조성물
RU2772025C2 (ru) ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ Lactobacillus plantarum
SP Effects of Resveratrol in a Mouse Model of Alcohol Addiction
US20190125810A1 (en) Bacillus subtilis containing composition for teatement of gastrointestinal irregulairty
Braun Comparison of Bacterial Phylogenetic Diversity in Rat Fecal Pellets and Cecum & Probiotic and Blueberry Treatment Effects on Bacterial Community Composition

Legal Events

Date Code Title Description
A107 Divisional application of patent
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701